Yazar "Ender, Fatma" seçeneğine göre listele

Listeleniyor 1 - 1 / 1
  • Küçük Resim
    Öğe
    Casirivimab/Imdevimab: Possible Candidate for COVID-19 Treatment in Pets: Traditional Review
    (Türkiye Klinikleri Yayınevi, 2023) Ender, Fatma; Sayıner, Serkan; Gençosman, Sevgi; Ceylanlı, Deniz; Özkurt, Güzin; Abacıoğlu, Nurettin; Özer Şehirli, Ahmet
    The coronavirus disease-2019 (COVID-19), over the last 3 years has globally resulted in catastrophic widespread losses. Prevention and control of this disease has become a global priority for researchers and medical professionals due to high mortality rates, treatment costs and various losses (economic and fatalities). In recent times, the fact that cats and dogs living in households which are being affected by the disease has caused panic among pet owners and animal lovers. Studies have shown that cats, especially young cats, are the group of animals which are most affected. Therefore, the treatment of COVID-19 in animals is an important topic for veterinary medicine. Monoclonal antibodies have also been considered a possible treatment modality due to the use of various agents to treat COVID-19 and the lack of clear demonstration of their efficacy. Casirivimab/imdevimab (CAS/IMD) is a monoclonal antibody cocktail approved for treating COVID-19. There was a high expectation that CAS/IMD combination directly affects the angiotensin converting enzyme-2 receptors, which plays an important role in the pathogenesis of the virus. Experimental and clinical studies have shown that CAS/IMD combination positively affects the prognosis of patients suffering from COVID-19, speeds up the recovery process and increases survival. We suggest that CAS/IMD can be considered protective in COVID-19 positive dogs and cats. The aim of this article is to review the studies related to the beneficial effects of CAS/IMD and its possible effectiveness in animals with COVID-19 to promote their research in future studies.